General Phase 2 study highlights flexible dosing options for tarlatamab in relapsed SCLCBy Healthcare Propulsion StaffSeptember 12, 20260 Extended-interval dosing regimens of tarlatamab demonstrated efficacy, safety and pharmacokinetic profiles generally consistent with the established every-two-week regimen in patients…
